During CKD, iron deficiency and chronic inflammation are two major factors contributing to hyporesponsiveness to erythropoietin treatment [8]. Inflammation, specifically through the increased production of hepcidin, plays a key role in this resistance by mediating iron sequestration. Here, EPO is linked to chronic kidney disease.